Answers are grounded in this paper and cite their sources.
Expert consensus update provides recommendations for SGLT2 inhibitors in heart failure, highlighting reduced hospitalizations and cardiovascular death across high-risk groups.
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Seferović et al. (2020) conducted a review in Heart failure and/or type 2 diabetes mellitus. Sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) was evaluated on Prevention of heart failure hospitalization and reduction of combined heart failure hospitalization and cardiovascular death. SGLT2 inhibitors (dapagliflozin or empagliflozin) are recommended to reduce HF hospitalization and cardiovascular death in symptomatic HFrEF regardless of type 2 diabetes status.
Synapse has enriched 10 related papers. Consider them for comparative context: